Invivyd Stock Price, News & Analysis

Invivyd (NASDAQ: IVVD) reported Q2 2025 financial results, highlighting $11.8 million in PEMGARDA® net product revenue, representing 413% year-over-year growth. The company announced positive Phase 1/2 data for VYD2311, their COVID-19 monoclonal antibody candidate, demonstrating favorable safety and a 76-day half-life for intramuscular administration.

The FDA has aligned on a rapid pathway to full approval (BLA) for VYD2311. The company's pipeline expansion includes RSV and measles candidates, with updates expected in Q3 and Q4 2025. Financial results showed a net loss of $14.7 million ($0.12 per share), improved from $47.2 million loss in Q2 2024, with $34.9 million in cash as of June 30, 2025.

Invivyd (NASDAQ: IVVD) has received FDA alignment on a streamlined pathway to potential BLA approval for VYD2311, its monoclonal antibody candidate for COVID-19 prevention. The FDA advised that a single Phase 2/3 randomized, double-blind, placebo-controlled trial could support BLA submission for broad population use (12+ years, 40kg+).

The clinical trial will evaluate two doses of VYD2311, featuring a 12-week primary endpoint analysis with potential extension to 24 weeks. The antibody demonstrates promising characteristics including a ~76-day half-life and high potency. The company positions VYD2311 as a non-vaccine alternative for COVID-19 prevention, targeting both immunocompromised individuals and the general population seeking protection.

Invivyd (Nasdaq: IVVD) has announced that Dr. Akiko Iwasaki, Professor of Immunobiology at Yale School of Medicine, has joined the SPEAR Study Group. The group was established to investigate the biology and clinical implications of persistent spike protein from SARS-CoV-2 virus and COVID-19 vaccines.

Dr. Iwasaki, co-Lead Investigator of the Yale COVID-19 Recovery Study, brings expertise in viral pathogenesis and post-viral conditions. The SPEAR Study Group was formed following reports that PEMGARDA® (pemivibart), Invivyd's FDA-authorized monoclonal antibody, showed potential benefits in Long COVID cases. The group plans to conduct clinical trials to evaluate monoclonal antibodies, including VYD2311, for treating Long COVID and Post-Vaccination Syndrome (PVS).

Invivyd (NASDAQ: IVVD) announced that the National Comprehensive Cancer Network (NCCN) has updated its guidelines to recommend monoclonal antibodies for COVID-19 prevention in cancer patients. This update aligns with guidance from IDSA and CDC, highlighting the importance of protecting immunocompromised individuals.

New research published in JAMA Oncology from the National Cancer Institute's study of 1,572 cancer patients with COVID-19 revealed concerning findings: high hospitalization rates, treatment disruptions, and significant complications. Notably, over 50% of cancer treatment disruptions were directly attributed to COVID-19, and of 290 initially hospitalized patients, 31 required readmission within 30 days for COVID-19 complications.

Invivyd (NASDAQ:IVVD) has established the SPEAR Study Group, a collaborative research initiative focused on investigating monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (PVS). The group was formed following multiple reports of clinical benefits from PEMGARDA® (pemivibart) in Long COVID patients.

The initiative brings together leading researchers including Drs. Michael Peluso, Amy Proal, and David Putrino to conduct rigorous clinical trials evaluating anti-SARS-CoV-2 spike protein monoclonal antibody therapy. The research aims to address conditions believed to be caused by persistent viral reservoirs or circulating spike protein, affecting approximately 5% of Americans.

While PEMGARDA is currently only FDA-authorized for COVID-19 prevention in immunocompromised individuals, the SPEAR Study Group will investigate its potential therapeutic applications for Long COVID, including the use of next-generation candidates like VYD2311.

Invivyd (NASDAQ: IVVD) announced positive Phase 1/2 clinical data for VYD2311, its next-generation COVID-19 monoclonal antibody. The trial demonstrated an excellent safety profile across all dosing methods (IV, SC, and IM), with only mild to moderate adverse events reported.

Key highlights include extended serum concentration duration, with the IM dose showing the longest half-life of 76.0 days. The antibody showed potential for long-term COVID-19 protection lasting multiple quarters, potentially exceeding vaccine durability. VYD2311 builds upon Invivyd's first-generation mAb, pemivibart, with 99%+ structural similarity but improved potency and resistance profile.

The company has scheduled a Type C meeting with FDA in early Q3 2025 to discuss registration-directed next steps and approval pathways for both prevention and treatment applications.

Invivyd (IVVD) has published results from its CANOPY Phase 3 clinical trial of PEMGARDA® (pemivibart) in Clinical Infectious Diseases. The trial, involving 788 adults across 18 sites, demonstrated 84% relative risk reduction in symptomatic COVID-19 compared to placebo over 6 months. The study included two cohorts: immunocompromised patients and people at risk due to regular indoor interactions. Key findings showed strong protection against modern, immune-evasive SARS-CoV-2 variants. The drug was generally well-tolerated, with mostly mild/moderate adverse events. Notable safety data included infusion-related reactions in 3.6% of Cohort A and 2.2% of Cohort B, and anaphylactic reactions in 0.6% of total participants. This marks the first and only clinical trial of an authorized COVID-19 monoclonal antibody with placebo-controlled data in a contemporary, seropositive U.S. population.

Invivyd (IVVD) announced that its monoclonal antibody PEMGARDA® (pemivibart) has been included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for B-Cell Lymphomas. This follows the Infectious Disease Society of America (IDSA) update in August 2024 recommending PEMGARDA for pre-exposure prophylaxis in immunocompromised patients. The drug is specifically authorized under FDA Emergency Use Authorization for COVID-19 prevention in moderate-to-severe immunocompromised patients aged 12 or older. PEMGARDA is engineered to maintain effectiveness against circulating SARS-CoV-2 variants, particularly benefiting patients with B-cell malignancies who may have reduced vaccine efficacy. This inclusion in NCCN Guidelines, supported by clinical and real-world evidence, represents a significant advancement in protecting vulnerable cancer patients from COVID-19 complications.

Invivyd (NASDAQ: IVVD) commends the FDA's new approach to evaluating COVID-19 medical interventions, particularly regarding vaccine boosters and monoclonal antibody treatments. The FDA now acknowledges uncertainty in COVID-19 vaccine booster efficacy and encourages manufacturers to conduct randomized, placebo-controlled trials. Invivyd's CANOPY Phase 3 trial of pemivibart demonstrated an 84% reduction in COVID-19 risk compared to placebo over six months, significantly exceeding the FDA's 30% threshold for "meaningful" protection. The company plans to advance improved antibodies for more scalable protection and expects to provide updates on their next-generation monoclonal antibody VYD2311 this quarter. Invivyd aims to engage with the FDA on expedited development pathways for high-risk populations.